Evidence map›Paper›PMID 30241151›Full record

Trial reportJournal of global oncology2018

Impact of Geographic Regions on Overall Survival in Patients With Metastatic Renal Cell Carcinoma: Results From an International Clinical Trials Database.

Andre P Fay, Rana R McKay, Xun Lin, Ronit Simantov, Toni K Choueiri

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of global oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Gut microbiota and immunotherapy of renal cell carcinoma.Human vaccines & immunotherapeutics · 2023
    Review
  3. Article
  4. Epidemiology of Renal Cell Carcinoma.World journal of oncology · 2020
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Andre P FayAndre P. Fay, Hospital São Lucas/Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil; Rana R. McKay, University of California San Diego, San Diego, CA; Xun Lin and Ronit Simantov, Pfizer Oncology, New York, NY; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.
Rana R McKayAndre P. Fay, Hospital São Lucas/Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil; Rana R. McKay, University of California San Diego, San Diego, CA; Xun Lin and Ronit Simantov, Pfizer Oncology, New York, NY; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.
Xun LinAndre P. Fay, Hospital São Lucas/Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil; Rana R. McKay, University of California San Diego, San Diego, CA; Xun Lin and Ronit Simantov, Pfizer Oncology, New York, NY; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.
Ronit SimantovAndre P. Fay, Hospital São Lucas/Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil; Rana R. McKay, University of California San Diego, San Diego, CA; Xun Lin and Ronit Simantov, Pfizer Oncology, New York, NY; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.
Toni K ChoueiriAndre P. Fay, Hospital São Lucas/Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil; Rana R. McKay, University of California San Diego, San Diego, CA; Xun Lin and Ronit Simantov, Pfizer Oncology, New York, NY; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHealth determinants vary according to geographic region and may affect the outcomes of patients with metastatic renal cell carcinoma (mRCC) treated during clinical trials of targeted therapy. Here, we investigate the overall survival (OS) of patients with mRCC treated in the era of targeted therapy by geographic region.

methodsWe conducted a pooled analysis of patients with mRCC who were treated during phase II or III clinical trials. Clinical characteristics and survival data were collected. Statistical analyses were performed with the Kaplan-Meier method and log-rank test in univariable analysis.

resultsOverall, 4,736 patients were included in the analysis. Patient characteristics differed according to geographic region. No statistically significant differences in OS were observed when the United States/Canada (USC) was compared with the following other regions: Latin America, Asia/Oceania/Africa, and Eastern Europe. In a univariable analysis, OS differed among patients enrolled in trials in USC compared with Western Europe (20.3 v 17.4 months; hazard ratio, 1.15; 95% CI, 1.03 to 1.3; P = .015), but it did not differ in a multivariable analysis. All-grade treatment-related adverse events (AEs) were observed more frequently in USC. There were no significant differences in grade 3 to 5 AEs among groups.

conclusionDespite different baseline characteristics, OS was similar among patients enrolled in clinical trials across different geographic regions. Access to clinical trials as well as disease biology, AE reporting, and quality of care may contribute to potential differences in outcomes.

Indexed as

Carcinoma, Renal CellFemaleHumansKidney NeoplasmsMaleMiddle AgedNeoplasm MetastasisRetrospective StudiesSurvival AnalysisTreatment Outcome

Identifiers

PMID30241151
PMCPMC6223429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.